BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for September 10, 2025, at 8:00 am ET. The webinar will feature Dr. Rachel Gafni, Senior Research Physician at the National Institute of Dental and Craniofacial Research (NIH) and Principal Investigator for the CALIBRATE Phase 3 trial.
The presentation will focus on autosomal dominant hypocalcemia type 1 (ADH1), including disease pathophysiology, unmet medical needs, and the potential of encaleret as a treatment. Executive team members will discuss the ongoing Phase 3 CALIBRATE study, with topline results expected in fall 2025.
BridgeBio Pharma (Nasdaq: BBIO) ha annunciato un webinar per gli investitori in programma per il 10 settembre 2025 alle 8:00 ET. L’evento vedrà la partecipazione della Dott.ssa Rachel Gafni, Senior Research Physician presso il National Institute of Dental and Craniofacial Research (NIH) e investigatore capo dello studio di fase 3 CALIBRATE.
La presentazione tratterà la ipoparatiroidismo autosomico dominante di tipo 1 (ADH1), illustrandone la fisiopatologia, i bisogni terapeutici non soddisfatti e il potenziale dell’encaleret come opzione di trattamento. I membri del management discuteranno lo studio CALIBRATE in corso di fase 3, con i risultati principali attesi per l’autunno 2025.
BridgeBio Pharma (Nasdaq: BBIO) anunció un seminario web para inversores programado para el 10 de septiembre de 2025 a las 8:00 am ET. El webinar contará con la participación de la Dra. Rachel Gafni, médica investigadora sénior en el National Institute of Dental and Craniofacial Research (NIH) y investigadora principal del ensayo de fase 3 CALIBRATE.
La presentación se centrará en la hipocalcemia autosómica dominante tipo 1 (ADH1), abordando la fisiopatología de la enfermedad, las necesidades médicas no cubiertas y el potencial del encaleret como tratamiento. Miembros del equipo ejecutivo hablarán sobre el estudio CALIBRATE en fase 3 en curso, con los resultados principales esperados en el otoño de 2025.
BridgeBio Pharma (Nasdaq: BBIO)는 2025년 9월 10일 오전 8시(ET)에 예정된 투자자 웨비나를 발표했습니다. 이번 웨비나에는 국립 치과·두개안면 연구소(NIDCR, NIH)의 선임 연구의사이자 CALIBRATE 3상 연구의 책임연구원인 Rachel Gafni 박사가 참여합니다.
발표는 상염색체 우성 저칼슘혈증 타입 1(ADH1)의 병태생리, 충족되지 않은 의료적 필요 및 치료제로서의 엔칼레렛의 가능성에 초점을 맞춥니다. 경영진도 진행 중인 3상 CALIBRATE 연구에 대해 논의하며, 주요 결과는 2025년 가을에 발표될 예정입니다.
BridgeBio Pharma (Nasdaq: BBIO) a annoncé un webinaire pour les investisseurs prévu le 10 septembre 2025 à 8h00 ET. Le webinaire accueillera la Dre Rachel Gafni, Senior Research Physician au National Institute of Dental and Craniofacial Research (NIH) et investigatrice principale de l’essai de phase 3 CALIBRATE.
La présentation portera sur l’hypocalcémie autosomique dominante de type 1 (ADH1), en abordant la physiopathologie de la maladie, les besoins médicaux non satisfaits et le potentiel de l’encaleret comme traitement. Des membres de l’équipe dirigeante commenteront l’étude CALIBRATE en cours de phase 3, avec des résultats principaux attendus à l’automne 2025.
BridgeBio Pharma (Nasdaq: BBIO) hat ein anstehendes Investoren-Webinar für den 10. September 2025 um 8:00 Uhr ET angekündigt. Am Webinar wird Dr. Rachel Gafni, Senior Research Physician am National Institute of Dental and Craniofacial Research (NIH) und leitende Prüferin der CALIBRATE Phase-3-Studie, teilnehmen.
Die Präsentation konzentriert sich auf die autosomal-dominante Hypokalzämie Typ 1 (ADH1), einschließlich Krankheitspathophysiologie, ungedeckter medizinischer Bedürfnisse und des Behandlungspotenzials von Encaleret. Mitglieder des Managements werden die laufende Phase-3-Studie CALIBRATE besprechen; die Hauptergebnisse werden für den Herbst 2025 erwartet.
- None.
- None.
PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company’s Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1).
Dr. Gafni will provide an overview of ADH1, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating encaleret as a treatment for ADH1.
In addition to Dr. Gafni, executive members of the ADH1 program team will review the ongoing encaleret clinical development program and discuss the ongoing Phase 3 CALIBRATE study, for which topline results are expected in fall 2025.
To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When is BridgeBio's ADH1 investor webinar and how can investors access it?
Who is presenting at BridgeBio's ADH1 investor webinar?
What is the focus of BridgeBio's upcoming investor webinar?
When are the topline results expected for BridgeBio's Phase 3 CALIBRATE study?
